Bentley inks insulin spray deal

Bentley Pharmaceuticals announced Monday that it has signed a licensing agreement to deliver insulin nasal spray products through much of the developing world.

The deal involves Biocon Ltd., based in Bangalore, India, which would supply the insulin and market it in some 85 companies in Asia, Africa and the Middle East. Both companies would work together in the clinical development and regulatory approval of the progress.

Financial details of the deal were not disclosed.

“We are pleased to team with one of the world’s largest producers of insulin and look forward to shaping an aggressive plan to develop our product,” said James R. Murphy, CEO if the Exeter, N.H.-based firm.

Insulin has traditionally been delivered via a needle, a process that is both expensive and potentially hazardous because it could lead to the spreading of infectious diseases. Biocon already has device that deliver the product orally, and the two companies are working with Indian regulatory authorities to approve a nasal delivery study in India. – NHBR STAFF